Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 151.54% | 183.68% | 407.86% | 2,471.78% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 151.54% | 183.68% | 407.86% | 2,471.78% | -- |
| Cost of Revenue | 42.47% | 43.00% | 50.12% | 23.14% | 22.13% |
| Gross Profit | 217.10% | 322.59% | 3,187.13% | 408.62% | 303.17% |
| SG&A Expenses | 75.22% | 64.79% | 60.52% | 90.97% | 189.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.45% | 60.21% | 57.89% | 71.19% | 125.82% |
| Operating Income | 33.39% | 30.26% | 45.06% | 38.53% | -1.47% |
| Income Before Tax | 38.90% | 29.70% | 44.84% | 40.18% | -5.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.90% | 29.70% | 44.84% | 40.18% | -5.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.90% | 29.70% | 44.84% | 40.18% | -5.94% |
| EBIT | 33.39% | 30.26% | 45.06% | 38.53% | -1.47% |
| EBITDA | 34.27% | 30.99% | 45.61% | 38.86% | -1.30% |
| EPS Basic | 45.44% | 36.93% | 54.30% | 52.27% | 24.89% |
| Normalized Basic EPS | 42.07% | 34.16% | 57.19% | 52.09% | 29.35% |
| EPS Diluted | 45.44% | 36.93% | 54.30% | 52.27% | 24.89% |
| Normalized Diluted EPS | 42.07% | 34.16% | 57.19% | 52.09% | 29.35% |
| Average Basic Shares Outstanding | 12.00% | 11.46% | 20.71% | 25.34% | 41.05% |
| Average Diluted Shares Outstanding | 12.00% | 11.46% | 20.71% | 25.34% | 41.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |